Previous 10 | Next 10 |
Results to be Presented at 2019 ASCO Annual Meeting Combination Demonstrates Significant Anti-Tumor Activity and Favorable Safety and Tolerability in Platinum-Resistant Disease Findings Support Ongoing Studies of Doublet Combination in Platinum-Agnostic Disease and Triplet in Plat...
Gainers : PDS Biotechnology (NASDAQ: PDSB ) +35% . Navios Maritime Holdings (NYSE: NM ) +26% . Cellectar Biosciences (NASDAQ: CLRB ) +21% . Nordic American Tankers (NYSE: NAT ) +14% . Ocean Bio-Chem (NASDAQ: OBCI ) +13% . Genetic Technologies (NASDAQ: GENE ) +13% . Amdocs (NASDAQ: DO...
ImmunoGen (NASDAQ: IMGN ) -31% . More news on: ImmunoGen, Inc., Sunworks, Inc., Co-Diagnostics, Inc., Stocks on the move Read more ...
ImmunoGen (NASDAQ: IMGN ) slips 5% premarket on light volume in reaction to its announcement that the FDA has recommended a new Phase 3 clinical trial evaluating antibody-drug conjugate mirvetuximab soravtansine in patients with high folate receptor alpha-positive, platinum-res...
Conference Call to be Held at 8:00 a.m. ET Today ImmunoGen, Inc. , (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced the United States Food and Drug Administration (FDA) has recommended that the Company con...
Gainers: Aquantia (NYSE: AQ ) +36% . Sinclair Broadcast (NASDAQ: SBGI ) +28% . Athenex (NASDAQ: ATNX ) +25% . Bridgeline Digital (NASDAQ: BLIN ) +22% . Regulus Therapeutics (NASDAQ: RGLS ) +18% . Ovid Therapeutics (NASDAQ: OVID ) +17% . Daxor Corporation (NYSEMKT: DXR ) +17% ....
Aquantia (NYSE: AQ ) +36% on $452M sale to Marvell. More news on: Aquantia Corp., Ovid Therapeutics Inc., Adaptimmune Therapeutics plc, Stocks on the move, Read more ...
Immunogen Inc. (IMGN) Q1 2019 Earnings Conference Call May 3, 2019 08:00 ET Company Participants Sarah Kiely - Director, Investor Relations and Corporate Communications Mark Enyedy - President and Chief Executive Officer Anna Berkenblit - Chief Medical Officer Rich Gregory - Ch...
ImmunoGen ( IMGN ) Q1 results : Revenues: $8.6M (-56.6%); Non-cash royalty revenue: $8.5M (+18.1%); License and milestone fees: $0.08M (-99.3%); R&D support: $0.02M (-95.0%). More news on: ImmunoGen, Inc., Healthcare stocks news, Earnings news and commentary, Stocks on the move, R...
ImmunoGen (NASDAQ: IMGN ): Q1 GAAP EPS of -$0.30 beats by $0.03 . More news on: ImmunoGen, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Klepierre (KLPEF) is expected to report for Q4 2023 comScore Inc. (SCOR) is expected to report $0.8 for Q4 2023 Universal Stainless & Alloy Products Inc. (USAP) is expected to report for Q4 2023 FAT Brands Inc. (FAT) is expected to report $-1.55 for Q4 2023 Jet.AI Inc. (JTAI) ...
AbbVie Completes Acquisition of ImmunoGen PR Newswire Adds flagship antibody-drug conjugate (ADC) ELAHERE ® (mirvetuximab soravtansine-gynx) for folate receptor-alpha (FRα) positive platinum-resistant ovarian cancer (PROC) to AbbVie's portfolio ...
2024-02-10 09:34:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...